What is BPC-157? What the research actually shows

BPC-157 is a 15-amino-acid synthetic peptide based on a sequence first reported from human gastric juice.^[1][2][3] It has been tested almost only in rats and mice, and whether it works or is safe in people is not established.^[4][3]

What it is

BPC-157 is also called PL 14736 or bepecin.^[3] No approved drug contains it in any country, and it is not in the European, Japanese or International Pharmacopeias.^[3]

Products sold online or by compounding pharmacies are made by chemical synthesis.^[5] The quality of what is sold online is unknown, and a review of the orthopaedic literature warns of unregulated manufacturing and contamination.^[4]

What the human evidence shows

There is very little.

• FDA's reviewers found one human efficacy trial, a randomised, double-blind trial of 53 adults with mild-to-moderate ulcerative colitis. They got an 80 mg BPC-157 enema or placebo once daily for 2 weeks. It is known only as a meeting abstract.^[3]
• In that trial the disease score fell by 3.2 points with BPC-157 and 1.6 with placebo. The 95% CI of -4.84 to 1.62 did not exclude no effect, and FDA called the data inadequate to support efficacy or safety.^[3]
• A chart review at one private clinic in Florida covered 17 people given BPC-157, alone or with thymosin beta-4, as a knee injection. Of 16 reached by phone, 14 reported pain relief. There was no control group and no validated outcome tool, and recall was 6 to 12 months later.^[6]
• A 2025 pilot gave 2 adults 10 mg and then 20 mg by IV infusion on consecutive days. The authors reported no side effects, but two people over 3 days cannot establish safety.^[7]
• A trial registered for 2027 (NCT07803250) is not yet recruiting. Its own description says BPC-157 has not undergone formal human clinical trials.^[8]

No published randomised, controlled trial in people has tested BPC-157 for tendon, muscle or joint injury.^[4][8]

What the animal and lab studies show

Most of the evidence is from rats. In rats with a cut Achilles tendon, BPC-157 given into the abdomen once daily improved recovery of load to failure, walking function and tendon structure over 14 days. This was reported by the group that originated the compound.^[9]

A 2026 rat study by a different group used 32 rats and gave BPC-157 10 µg/kg/day for 4 weeks.^[10] Load to failure was higher than in controls but not significantly.^[10] Tendon scores were numerically better but not significant for BPC-157 alone.^[10] The TB-500 group, not the BPC-157 group, reached significance.^[10]

In rat tendon cells grown in culture, BPC-157 raised growth hormone receptor expression. This is a cell-culture finding and does not show an effect in people.^[11]

Rat studies from the same group report protection in a long list of injury models, including colitis and ischaemia-reperfusion. FDA's reviewers noted that dose-response relationships and molecular targets have not been established and the mechanism remains poorly understood.^[12][13][3]

Authorship is also concentrated. In the records we hold, 31 of 158 animal records list Sikiric or Seiwerth among their first three authors, and the real count is higher because author lists are truncated.^{[14][9][12][15]} Independent replications exist but are few.^[10][1]

Safety and legal status

Human safety data are almost absent. FDA's reviewers found no studies of oral, subcutaneous, nasal or skin use in people. They found only two rectal-enema studies of up to 2 weeks, which reported no serious adverse events with limited safety monitoring.^[3]

Reports to FDA's adverse event system included injection site reaction, shortness of breath, and gum and skin darkening. FDA said it was unclear whether BPC-157 caused them.^[3]

FDA also flagged a risk of immune reactions for injected and nasal peptides because of aggregation and impurities.^[3][16]

In animals, a published preclinical package in mice, rats, rabbits and dogs found no serious toxicity.^[17][1]

On regulation:

• As of 2026-10-09, BPC-157 is not approved by FDA. FDA's category 2 page lists it among substances previously in category 2 for significant safety risks.^[16]
• FDA's briefing document proposed not adding BPC-157 to the 503A bulks list. It judged the substance not well characterised, found a lack of evidence of effectiveness for ulcerative colitis, and found insufficient safety information.^[3]
• ABC News reportedly said the advisory committee narrowly voted to recommend adding it, against the FDA staff view. This is a secondary report, and the vote is advisory and non-binding.^[18]
• USADA says BPC-157 is prohibited in sport under the WADA S0 category.^[5]

The bottom line

Much of the rat work on BPC-157 comes from one research group and has not been broadly reproduced.^[10][19] In people, the evidence is one inconclusive abstract, a small uncontrolled chart review and a two-person safety pilot.^[3][6][7]

Our sources show no human pharmacokinetic data, no long-term safety data, no carcinogenicity studies, and no drug interaction studies.^[3] Anyone weighing it should know that the honest answer today is that we do not know if it works or if it is safe in people.